Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma (NCT05561816) | Clinical Trial Compass
CompletedPhase 3
Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma
Russia240 participantsStarted 2022-07-19
Plain-language summary
The study is aimed to:
* evaluate the effectiveness of 10-day therapy with Dioxidin® compared with Miramistin® in the treatment of superficial pyoderma,
* evaluate the safety and tolerability of 10-day therapy with Dioxidin® compared with Miramistin® for the treatment of superficial pyoderma.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
âś“. Men and women between the ages of 18 and 65 years inclusive.
âś“. Signed informed consent form to participate in the study.
âś“. Patients with superficial pyoderma of different localization.
✓. Body surface lesion area ≤ 5%.
âś“. Patient's willingness and ability to comply with protocol requirements throughout the study (in particular, willingness to adhere strictly to the prescribed treatment regimen and to record the time of drug administration in the patient's diary).
âś“. Consent of study participant with preserved reproductive potential to use adequate methods of contraception (e.g., dual barrier method) throughout the study and for 3 weeks after study completion.
Exclusion criteria
âś•. Hypersensitivity to the active and/or excipients of the studied drugs.
âś•. Presence of signs of acute respiratory infections.
âś•. Deep pyoderma (furunculus, carbuncle, abscess, hydradenitis, etc.).
âś•. Use of local and systemic antibacterials, antiseptics, glucocorticosteroids, and antifungal agents less than 14 days prior to the screening visit.